Disclaimer: This information is intended for educational purposes and as a comprehensive clinical reference for healthcare professionals. It is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare provider, considering the individual patient's specific circumstances and the latest available evidence and guidelines. Medications, dosages, and treatment protocols may change, and clinicians must verify all information with current prescribing information and institutional policies.

---

Primary Hyperoxalosis

Overview

• Definition: Primary hyperoxalosis (PH) refers to a group of rare, inherited (autosomal recessive) metabolic disorders characterized by the excessive endogenous production of oxalate, primarily by the liver. This overproduction leads to pathological accumulation and precipitation of calcium oxalate crystals in the kidneys (nephrocalcinosis and urolithiasis), causing progressive kidney damage and eventually end-stage kidney disease (ESKD). Once ESKD occurs, oxalate accumulates in virtually all body tissues, a condition known as systemic oxalosis, leading to widespread organ damage.
• Epidemiology: PH is a very rare disease with an estimated incidence of 1-3 cases per million live births in Europe and North America, and a prevalence of 1-9 cases per million population. It is more prevalent in regions with high rates of consanguinity. PH1 is the most common and severe form, accounting for approximately 80% of all PH cases, followed by PH2 and PH3, each accounting for about 10% of cases.
• Classification:
  • Primary Hyperoxaluria Type 1 (PH1): Caused by mutations in the AGXT gene, leading to a deficiency of the peroxisomal enzyme alanine-glyoxylate aminotransferase (AGT) in the liver. AGT is responsible for converting glyoxylate to glycine. Its deficiency leads to the accumulation of glyoxylate, which is then aberrantly converted to oxalate.
  • Primary Hyperoxaluria Type 2 (PH2): Caused by mutations in the GRHPR gene, resulting in a deficiency of the cytosolic enzyme glyoxylate reductase/hydroxypyruvate reductase (GRHPR). This enzyme normally converts glyoxylate to glycolate and hydroxypyruvate to D-glycerate. Its deficiency leads to increased glyoxylate (and thus oxalate) and L-glycerate.
  • Primary Hyperoxaluria Type 3 (PH3): Caused by mutations in the HOGA1 gene (encoding 4-hydroxy-2-oxoglutarate aldolase). HOGA1 is involved in the hydroxyproline degradation pathway. Its deficiency leads to an accumulation of 4-hydroxy-2-oxoglutarate, which is then converted to glyoxylate and subsequently to oxalate.

Pathophysiology

• Mechanism:
  • PH1: In the liver peroxisomes, glyoxylate is a metabolic intermediate. Normally, AGT converts glyoxylate to glycine. When AGT is deficient or functionally impaired due to AGXT mutations, glyoxylate accumulates and is shunted to lactate dehydrogenase (LDH), which converts it to oxalate. This oxalate is then excreted by the kidneys. As kidney function deteriorates due to nephrocalcinosis and recurrent stones, the kidneys' ability to excrete oxalate diminishes. When the glomerular filtration rate (GFR) falls below approximately 30-40 mL/min/1.73m², plasma oxalate levels rise dramatically, leading to systemic deposition of calcium oxalate crystals in extra-renal tissues (e.g., bones, heart, retina, blood vessels), causing widespread organ damage.
  • PH2: The GRHPR gene encodes an enzyme that reduces glyoxylate to glycolate and hydroxypyruvate to D-glycerate. Deficiency leads to accumulation of glyoxylate (which is converted to oxalate) and L-glycerate. Although L-glycerate accumulates, it does not directly contribute to oxalate formation but serves as a diagnostic marker. The disease course is generally milder than PH1, with less systemic oxalosis and slower progression to ESKD.
  • PH3: The HOGA1 gene product is involved in the catabolism of hydroxyproline. Its deficiency leads to accumulation of 4-hydroxy-2-oxoglutarate, which is metabolized to glyoxylate, and subsequently to oxalate. PH3 typically has a milder phenotype than PH1, often characterized by recurrent calcium oxalate kidney stones but less frequent progression to ESKD or systemic oxalosis, though variable presentations exist.
• Risk Factors: The primary risk factor is inheriting two copies of a mutated gene (AGXT, GRHPR, or HOGA1), as PH follows an autosomal recessive inheritance pattern. Consanguinity significantly increases the risk due to the higher probability of inheriting two copies of rare recessive alleles.
• Protective Factors: There are no known protective factors against developing the genetic defect. However, early diagnosis and aggressive, sustained medical management can significantly mitigate the progression of kidney disease and the development of systemic complications.

Clinical Presentation

Signs and Symptoms

The clinical presentation of PH is highly variable, ranging from rapid progression to ESKD in infancy to late-onset disease in adulthood.

• Cardinal Features:

  • Nephrolithiasis/Urolithiasis: Recurrent, often bilateral, calcium oxalate kidney stones. This is the most common presentation, especially in childhood and adolescence.
  • Nephrocalcinosis: Diffuse calcification of the renal parenchyma, frequently bilateral, leading to progressive loss of kidney function.
  • Progressive Chronic Kidney Disease (CKD): Leading to End-Stage Kidney Disease (ESKD) in most patients with PH1 and a subset of PH2/PH3 patients.
  • Systemic Oxalosis: Occurs primarily in PH1, especially once GFR falls below 30-40 mL/min/1.73m² and plasma oxalate levels rise significantly. This involves oxalate deposition in non-renal tissues.

• Early Signs:

  • Infancy: Failure to thrive, recurrent urinary tract infections (UTIs), hematuria, polyuria/polydipsia, hyperoxaluria, and often severe nephrocalcinosis diagnosed on ultrasound.
  • Childhood/Adolescence: Recurrent episodes of renal colic, abdominal pain, flank pain, gross or microscopic hematuria, passage of stones, and signs of progressive CKD (e.g., fatigue, growth retardation, anemia).
• Advanced Signs: Manifestations of ESKD and systemic oxalosis.
  • Uremic symptoms: Nausea, vomiting, fatigue, pruritus.
  • Musculoskeletal: Oxalate osteopathy (bone pain, pathological fractures, severe rickets-like changes, joint pain/arthropathy), growth plate abnormalities.
  • Cardiovascular: Cardiomyopathy (congestive heart failure), cardiac conduction abnormalities, arrhythmias (due to oxalate deposition in myocardium and conduction system).
  • Hematological: Refractory anemia (due to bone marrow oxalate infiltration), thrombocytopenia, leukopenia.
  • Vascular: Peripheral vasculopathy (digital ischemia, gangrene, livido reticularis, skin ulcers).
  • Ocular: Retinal pigmentary changes ("sparkling retina" or "salt and pepper" appearance due to oxalate deposits), visual impairment.
  • Neurological: Peripheral neuropathy (rare).
  • Dental: Enamel hypoplasia, dental pain.
• Atypical Presentations:
  • Late-onset presentation in adulthood, often resembling idiopathic calcium oxalate stone disease, particularly in milder PH1 variants, PH2, or PH3.
  • Presentation as isolated kidney stones without significant nephrocalcinosis (more common in PH2/PH3).
  • Presenting with only systemic oxalosis features in a patient with undiagnosed ESKD.

Physical Examination

Findings depend on the stage of the disease and severity of systemic involvement.

• Inspection:
  • General: Pallor (anemia), signs of chronic illness, failure to thrive or growth retardation (in children), cachexia.
  • Skin: Livido reticularis, subcutaneous nodules, digital ischemia, skin ulcers, acrocyanosis.
  • Eyes: On ophthalmoscopy, characteristic "sparkling retina" (diffuse, shimmering refractile deposits in the retina and vitreous) due to oxalate crystal deposition, optic atrophy.
  • Musculoskeletal: Bony deformities (rickets-like changes), short stature, joint swelling or tenderness.
• Palpation:
  • Kidneys: May be palpable if enlarged due to hydronephrosis from obstructing stones; otherwise, not typically enlarged by the underlying disease process.
  • Bones: Tenderness over long bones, joints, or spine due to oxalate osteopathy.
• Special Tests:
  • Cardiac Auscultation: May reveal murmurs, gallop rhythms, or signs of heart failure.
  • Neurological Examination: May show signs of peripheral neuropathy (e.g., diminished sensation or reflexes in advanced cases).

Diagnostic Approach

History Taking

• Key Questions:
  • Family History: Any family members with a history of kidney stones, nephrocalcinosis, unexplained kidney failure, dialysis, or kidney transplantation? Known diagnosis of PH in the family? (Important due to autosomal recessive inheritance).
  • Age of Onset: When did kidney stone symptoms first appear? Early onset (infancy/childhood) strongly suggests PH.
  • Stone Characteristics: Frequency of stone episodes, need for interventions, stone analysis results (if available, pure calcium oxalate monohydrate is highly suspicious).
  • Kidney Disease Progression: Has there been progressive decline in kidney function? Was nephrocalcinosis noted on prior imaging?
  • Systemic Symptoms: Any unexplained bone pain or pathological fractures? Cardiac symptoms (shortness of breath, palpitations)? Visual changes? Skin lesions? These point to systemic oxalosis.
  • Dietary History: To differentiate from secondary hyperoxaluria, inquire about excessive intake of oxalate-rich foods (e.g., spinach, rhubarb, chocolate, nuts, tea) or conditions causing enteric hyperoxaluria (e.g., inflammatory bowel disease, bariatric surgery). While PH is primarily endogenous production, dietary factors can contribute.
• Red Flags:
  • Recurrent calcium oxalate kidney stones in infancy or childhood.
  • Bilateral nephrocalcinosis, especially in pediatric patients.
  • Progressive CKD of unknown etiology, particularly if accompanied by hyperoxaluria.
  • Family history of early-onset ESKD or recurrent stones.
  • Stone analysis revealing pure calcium oxalate monohydrate.
  • Systemic symptoms (bone pain, cardiac issues, vision changes) in a patient with kidney disease.

Laboratory Tests

• First-Line:
  • 24-hour Urine Collection: For oxalate, creatinine, calcium, citrate, and other stone-forming compounds.
    • Urinary Oxalate: Markedly elevated (> 45 mg/day/1.73m² or > 0.5 mmol/24h/1.73m²) is the hallmark. In PH1, oxalate excretion can be extremely high (>100 mg/day). In children, reference ranges are age-dependent; urine oxalate-to-creatinine ratio (Ox:Cr) is often used (e.g., >0.07 mg/mg in adults, higher in infants/young children).
    • Urinary Glycolate: Elevated in PH1 (> 83 mg/day/1.73m² or >0.9 mmol/day/1.73m²).
    • Urinary L-Glycerate: Elevated in PH2 (> 12 mg/day/1.73m² or >0.14 mmol/day/1.73m²).
    • Urinary 4-hydroxy-2-oxoglutarate (HOG): Elevated in PH3.
  • Plasma Oxalate: Crucial for diagnosis and monitoring, especially as GFR declines. Normal range is typically < 10-15 µmol/L. Levels are often significantly elevated in PH patients, particularly once CKD progresses.
  • Serum Creatinine, BUN, Electrolytes, eGFR: To assess kidney function and metabolic status.
  • Stone Analysis: If a stone is passed or removed, analysis should be performed. Pure calcium oxalate monohydrate suggests PH.
• Confirmatory:
  • Genetic Testing: This is the gold standard for definitive diagnosis and differentiation of PH types. It involves sequencing the AGXT, GRHPR, and HOGA1 genes. Identification of pathogenic mutations confirms the diagnosis and guides treatment decisions (e.g., pyridoxine responsiveness in PH1).
  • Liver Biopsy (Enzyme Assay): Historically used to measure AGT enzyme activity in liver tissue for PH1 diagnosis. Rarely performed now due to the widespread availability and accuracy of genetic testing, but may be considered in very rare, equivocal cases.
• Monitoring:
  • 24-hour Urine Oxalate, Glycolate, L-Glycerate: To monitor response to medical therapies.
  • Plasma Oxalate: Regular monitoring is essential, especially in PH1, to assess disease progression, adequacy of dialysis, and readiness for transplantation.
  • Serum Creatinine, eGFR: Regular assessment of kidney function.
  • Complete Blood Count, Calcium, Phosphate, PTH, Alkaline Phosphatase: To monitor for anemia and bone disease (CKD-MBD and oxalate osteopathy).
  • ECG and Echocardiogram: To monitor for cardiac involvement (cardiomyopathy, arrhythmias).
  • Ophthalmoscopy: For serial evaluation of retinal oxalate deposits.

Imaging

• Recommended:
  • Renal Ultrasound: First-line imaging. Will demonstrate nephrocalcinosis (hyperechoic renal pyramids, often bilateral) and/or hydronephrosis due to obstructing stones. It is also useful for monitoring the progression of nephrocalcinosis and stone burden.
  • Kidney, Ureter, Bladder (KUB) X-ray: Can visualize radiopaque calcium oxalate stones and diffuse nephrocalcinosis.
  • Non-contrast Computed Tomography (CT) KUB: Most sensitive imaging modality for detecting renal calculi and nephrocalcinosis. Provides detailed information for surgical planning and assessing stone burden.
• Advanced:
  • Bone Scan (Technetium-99m Methylene Diphosphonate - MDP): May show increased uptake in bones indicative of widespread oxalate deposition (oxalate osteopathy), particularly useful in advanced systemic oxalosis.
  • Cardiac MRI/Echocardiogram: To assess for oxalate cardiomyopathy, ventricular dysfunction, and cardiac chamber enlargement.
  • MRI (Brain/Peripheral Nerves): If neurological symptoms are present, though rare.

Management

Acute Management

• Immediate:
  • Urosepsis/Obstructive Uropathy: Urgent urological intervention (e.g., percutaneous nephrostomy, ureteral stent) for relief of obstruction and drainage of infected urine. Prompt broad-spectrum antibiotics.
  • Acute Kidney Injury (AKI): Manage fluid and electrolyte imbalances (e.g., hyperkalemia, severe metabolic acidosis) according to standard AKI protocols. Address reversible causes of AKI (e.g., obstruction).
• Stabilization:
  • Pain Management: For renal colic associated with kidney stones, using analgesics (NSAIDs if GFR allows, opioids).
  • Hydration: Promote high fluid intake (oral or intravenous) to ensure adequate urine output and facilitate stone passage, while carefully monitoring fluid balance in patients with impaired kidney function.
• Emergency:
  • Dialysis: Initiated for life-threatening complications of ESKD, such as refractory hyperkalemia, severe metabolic acidosis, pulmonary edema, or uremic encephalopathy. It serves as a bridge to definitive therapy.

Chronic Management

The cornerstone of chronic management is to reduce oxalate production and/or enhance oxalate excretion, prevent crystal deposition, and manage complications.

• Pharmacological:
  • Hyperhydration: Maintain a high urine output to prevent calcium oxalate supersaturation.
    • Dosage: Aim for urine volume of 2-3 L/day in adults, or 2 L/m²/day in children. Encourage continuous oral fluid intake throughout the day and night.
  • Crystallization Inhibitors:
    • Potassium Citrate: Increases urinary citrate (a potent inhibitor of calcium oxalate crystallization) and raises urinary pH, which increases calcium oxalate solubility.
      • Dosage: Typically 0.1-0.15 g/kg/day orally in 3-4 divided doses (e.g., 60-120 mEq/day in adults). Titrate to achieve a urinary pH of 6.5-7.0 and target urinary citrate levels.
    • Orthophosphate: Less commonly used, can inhibit crystal formation.
  • Pyridoxine (Vitamin B6): Co-factor for the AGT enzyme. Effective in a subset (approximately 30-50%) of PH1 patients who have residual AGT activity that can be stimulated by pyridoxine.
    • Dosage: Initiate with 5 mg/kg/day orally, gradually increasing up to 20 mg/kg/day (maximum 500 mg/day for adults). Response is assessed by reduction in 24-hour urinary oxalate excretion over 3-6 months. If no significant reduction (e.g., <20-30%) at the maximum dose, the patient is considered pyridoxine non-responsive. Monitor for peripheral neuropathy with high doses.
  • Novel Therapies (RNA Interference - RNAi): These therapies target the hepatic synthesis of oxalate precursors.
    • Lumasiran (OXLUMO®): Approved for PH1. An RNAi therapeutic that reduces the hepatic production of glycolate oxidase (GO), an enzyme upstream of glyoxylate formation. By reducing GO, glyoxylate (and thus oxalate) production is reduced.
      • Dosage: Subcutaneous injection. Loading dose: 3 mg/kg once monthly for 3 doses. Maintenance dose: 3 mg/kg every 3 months. Dosage adjustments for severe renal impairment or ESKD are not typically required.
    • Nedosiran (RIVFLOZA™): Approved for PH1 and PH2. An RNAi therapeutic that reduces the hepatic production of lactate dehydrogenase (LDH), which converts glyoxylate to oxalate.
      • Dosage: Subcutaneous injection. Loading dose: 160 mg once monthly for 3 doses. Maintenance dose: 160 mg every month. (Dosage adjusted for body weight in children).
    • Rationale: These therapies represent a major breakthrough, offering significant and sustained reductions in urinary and plasma oxalate, improving renal function in some patients, and reducing systemic oxalate burden.
  • Renal Replacement Therapy (RRT):
    • Dialysis: Once ESKD develops, dialysis (hemodialysis or peritoneal dialysis) is necessary. However, conventional dialysis is generally inadequate for oxalate removal due to the continuous endogenous production of oxalate and its poor dialyzability (protein binding).
      • Intensive Hemodialysis: For PH1 patients awaiting combined liver-kidney transplantation, intensive (daily, prolonged sessions, e.g., 6-8 hours/day or nocturnal HD) hemodialysis is often necessary to minimize plasma oxalate levels and slow the progression of systemic oxalosis, though it cannot normalize oxalate.
    • Combined Liver-Kidney Transplantation: The definitive and curative treatment for PH1. The transplanted healthy liver provides the missing AGT enzyme, normalizing oxalate production. A kidney transplant is then performed, ideally simultaneously or soon after the liver transplant, to replace the damaged kidneys. Pre-emptive transplantation (before ESKD) is ideal to prevent systemic oxalosis, but is rarely feasible.
    • Isolated Kidney Transplantation: May be considered for PH2 and PH3. For PH1, kidney transplant alone is generally contraindicated unless performed after or concurrently with liver transplant, as oxalate would rapidly re-deposit in the new kidney. In PH2/PH3, the enzymatic defect is not solely in the liver (PH2) or is less severe/systemic (PH3), so isolated kidney transplant may be successful, but careful pre- and post-transplant oxalate management is still crucial.
• Non-pharmacological:
  • Dietary Modifications: While genetic PH involves endogenous oxalate production, avoiding extremely high oxalate foods (e.g., spinach, rhubarb, chocolate, nuts, tea) may be considered as an adjunct, but it is not a primary treatment and its impact on overall oxalate load in PH is limited compared to endogenous production. Calcium restriction is generally discouraged as it can increase oxalate absorption from the gut.
  • Surgical/Endourological Interventions: For symptomatic kidney stones (e.g., extracorporeal shockwave lithotripsy (ESWL), ureteroscopy, percutaneous nephrolithotomy (PCNL)) as needed.

Treatment Algorithms

• First-Line:
  1. Diagnosis and Genetic Confirmation: Establish diagnosis of PH and identify the specific type (PH1, PH2, PH3) through genetic testing.
  2. General Measures for All Types:
     • Hyperhydration: Maintain high urine volume (2-3 L/day for adults, 2 L/m²/day for children).
     • Potassium Citrate: Administer to increase urinary citrate and pH.
  3. Type-Specific Initial Therapy:
     • PH1:
       • Pyridoxine Responsiveness Test: Trial pyridoxine (5-20 mg/kg/day, max 500 mg/day). If significant reduction in urinary oxalate (e.g., >20-30%) after 3-6 months, continue pyridoxine.
       • If pyridoxine-responsive PH1: Continue pyridoxine + hyperhydration + citrate. Consider adding Lumasiran/Nedosiran if response is partial or inadequate, or for patients with advanced disease.
       • If pyridoxine-non-responsive PH1: Initiate Lumasiran (OXLUMO®) or Nedosiran (RIVFLOZA™) + hyperhydration + citrate. These are the current first-line treatments for non-responsive PH1.
     • PH2 & PH3: Hyperhydration + citrate. Nedosiran (RIVFLOZA™) is approved for PH2. For PH3, conservative measures are generally sufficient, with close monitoring.
• Second-Line:
  • If medical therapy fails to control hyperoxaluria, kidney function progressively declines, or severe systemic oxalosis develops despite optimal medical management:
    • PH1: Referral for combined liver-kidney transplantation. This is the definitive cure. Ideal candidates are those without severe, irreversible systemic oxalosis. If ESKD is present, initiate intensive daily hemodialysis while awaiting transplantation.
    • PH2 & PH3: Referral for isolated kidney transplantation. Liver transplantation is generally not indicated. Careful pre- and post-transplant management of oxalate is vital to prevent recurrence in the new kidney.
• Refractory Cases:
  • Patients who progress to ESKD despite aggressive medical management.
  • Patients developing severe, life-threatening systemic oxalosis (e.g., severe cardiomyopathy, extensive bone disease, severe peripheral vasculopathy).
  • These scenarios necessitate urgent evaluation for transplantation (combined liver-kidney for PH1, kidney for PH2/3), emphasizing the need for comprehensive multidisciplinary care.

Complications

• Common:
  • Recurrent calcium oxalate nephrolithiasis and nephrocalcinosis.
  • Progressive chronic kidney disease (CKD) leading to end-stage kidney disease (ESKD).
  • Recurrent urinary tract infections (UTIs) due to stones.
  • Growth retardation in children.
• Serious:
  • Systemic Oxalosis: The most severe complication, occurring once GFR is severely impaired.
    • Cardiac: Cardiomyopathy, heart failure, arrhythmias, conduction defects. This is a leading cause of mortality in severe PH1.
    • Skeletal: Severe oxalate osteopathy (pathological fractures, bone pain, rickets-like deformities, growth plate abnormalities).
    • Hematological: Refractory anemia due to bone marrow infiltration, thrombocytopenia.
    • Vascular: Peripheral vasculopathy leading to digital ischemia, gangrene, skin ulcers, livedo reticularis.
    • Ocular: Retinal oxalate deposits ("sparkling retina"), visual impairment.
    • Neurological: Peripheral neuropathy (less common).
  • Urosepsis and sepsis from recurrent UTIs.
  • Complications associated with chronic dialysis (e.g., amyloidosis, access issues).
  • Complications associated with transplantation (e.g., rejection, infection, malignancy).
• Long-term:
  • Chronic pain from stones or oxalate osteopathy.
  • Significantly reduced quality of life due to chronic illness, dialysis, and systemic complications.
  • Lifelong dependence on renal replacement therapy or immunosuppression post-transplant.
  • Increased mortality, particularly in severe PH1 without timely transplantation.

Prognosis

• Factors:
  • Genetic Type: PH1 generally has the most severe prognosis, with rapid progression to ESKD, often in childhood. PH2 and PH3 typically have a milder course, with slower progression and many patients reaching adulthood with preserved kidney function, although ESKD can still occur.
  • Age of Onset: Earlier age of onset (infancy) in PH1 is associated with more aggressive disease and poorer prognosis.
  • Pyridoxine Responsiveness (for PH1): Pyridoxine-responsive PH1 patients generally have a better prognosis and slower disease progression compared to non-responsive patients, as pyridoxine reduces oxalate production.
  • Timeliness of Diagnosis and Intervention: Early diagnosis and initiation of aggressive medical therapy (including new RNAi therapies) significantly improve renal outcomes and can delay or prevent ESKD and systemic oxalosis.
  • Access to Transplantation: For PH1, successful combined liver-kidney transplantation dramatically improves prognosis and is curative for the underlying metabolic defect. For PH2/3, isolated kidney transplantation can be life-saving.
• Survival: Without definitive treatment, the prognosis for severe PH1 is poor, with many patients dying from ESKD or complications of systemic oxalosis by adolescence or early adulthood. The median age of death for untreated PH1 can be as low as 5-15 years. With successful transplantation, survival rates improve significantly.
• Quality of Life: Heavily impacted by chronic kidney disease, recurrent stones, the burden of dialysis, and complications of systemic oxalosis. Successful transplantation can substantially improve quality of life, but patients still face lifelong immunosuppression and the potential for transplant-related complications.

Prevention

• Primary: Prevention of the genetic defect itself is not possible. However, genetic counseling is crucial for families with a known history of PH to understand the autosomal recessive inheritance pattern and recurrence risks. Preimplantation genetic diagnosis (PGD) or prenatal diagnosis (chorionic villus sampling or amniocentesis) can be offered to at-risk couples.
• Secondary: Focuses on early diagnosis and intervention to prevent or slow disease progression.
  • Early Diagnosis: Prompt investigation of any child or young adult presenting with recurrent calcium oxalate kidney stones, bilateral nephrocalcinosis, or unexplained progressive CKD should include evaluation for PH, especially with 24-hour urine oxalate, glycolate, L-glycerate, and ultimately genetic testing.
  • Early Initiation of Medical Therapy: As soon as PH is diagnosed, aggressive medical management with hyperhydration, potassium citrate, pyridoxine (if PH1 responsive), and newer RNAi therapies (Lumasiran, Nedosiran) should be initiated to reduce oxalate burden and delay kidney function decline.
• Tertiary: Aimed at preventing complications in patients with established disease.
  • Preventing ESKD Progression: Through meticulous adherence to medical therapy and early consideration of transplantation.
  • Preventing Systemic Oxalosis: By maintaining the lowest possible plasma oxalate levels, particularly in PH1 patients, through intensive dialysis while awaiting transplantation.
  • Preventing Complications of RRT and Transplantation: Standard care for patients on dialysis and post-transplant, including close monitoring for infection, rejection, and medication side effects.

Special Populations

• Pediatric:
  • Most PH cases present in childhood, with infantile forms of PH1 being particularly aggressive and rapidly progressive.
  • Growth retardation is a common and significant concern that requires close monitoring and nutritional support.
  • Medication dosages (e.g., pyridoxine, Lumasiran, Nedosiran, potassium citrate) are weight- or body surface area-based.
  • Intensive daily hemodialysis is often critical for very young children with ESKD awaiting combined liver-kidney transplantation to manage severe hyperoxalemia and prevent systemic oxalosis.
  • Early referral to pediatric nephrology and transplant centers is paramount.
• Geriatric:
  • Extremely rare to present in the elderly, as severe PH types typically manifest much earlier. Milder variants or PH2/3 may be diagnosed in adulthood, sometimes after years of recurrent kidney stone disease mistaken for idiopathic calcium oxalate stones.
  • Management needs to consider existing comorbidities, polypharmacy, and overall functional status.
• Pregnancy:
  • Data on PH management during pregnancy is limited. Management focuses on maintaining optimal hydration and managing hyperoxaluria.
  • Genetic counseling is important for affected women and their partners.
  • The safety of newer RNAi therapies (Lumasiran, Nedosiran) during pregnancy is not well established; risk-benefit assessment is required in consultation with specialists.
• Comorbidities:
  • Kidney Stones: Ongoing need for urological evaluation and interventions for symptomatic stones.
  • Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD): PH patients, especially those with systemic oxalosis, are at high risk for severe bone disease exacerbated by oxalate osteopathy. Aggressive management of calcium, phosphate, and PTH is crucial.
  • Cardiovascular Disease: Increased risk due to systemic oxalosis affecting the heart and the general risks associated with CKD. Close monitoring and standard management of heart failure and arrhythmias.

Clinical Pearls

• Diagnostic:
  • Think PH in pediatric stone formers: Always consider primary hyperoxaluria in any child with recurrent calcium oxalate kidney stones, bilateral nephrocalcinosis, or unexplained progressive kidney disease.
  • Plasma vs. Urine Oxalate: While 24-hour urine oxalate is the initial diagnostic test, plasma oxalate levels become critically important for diagnosis and monitoring once GFR declines (<30 mL/min/1.73m²), as urine oxalate excretion may paradoxically decrease.
  • Genetic Testing is Key: Genetic analysis (AGXT, GRHPR, HOGA1) is the definitive diagnostic test and crucial for differentiating PH types, which dictates management (e.g., pyridoxine responsiveness).
  • Don't confuse with secondary hyperoxaluria: Primary hyperoxaluria typically results in much higher oxalate levels (urinary and plasma) than secondary forms (e.g., enteric hyperoxaluria due to fat malabsorption, dietary overload), though these should be considered in the differential.
• Treatment:
  • Hyperhydration and Citrate are Foundation: Maintaining high urine volume and administering potassium citrate are essential first-line treatments for all PH types to reduce calcium oxalate supersaturation.
  • Pyridoxine for PH1: Always test for pyridoxine responsiveness in PH1 patients, as responders can significantly benefit from this safe and inexpensive therapy.
  • RNAi Therapies are Game-Changers: Lumasiran and Nedosiran represent a major advance for PH1 (and Nedosiran for PH2), offering targeted reduction in oxalate production, potentially delaying or preventing ESKD and systemic oxalosis.
  • Liver Transplant is Curative for PH1: Combined liver-kidney transplantation is the only curative treatment for PH1. Early referral to a specialized transplant center, ideally pre-ESKD if feasible, is paramount to prevent irreversible systemic organ damage.
  • Intensive Dialysis for PH1 ESKD: For PH1 patients on ESKD awaiting transplant, standard dialysis is inadequate for oxalate removal. Daily, prolonged hemodialysis sessions are necessary to mitigate systemic oxalosis.
• Pitfalls:
  • Misdiagnosis: Failing to consider PH in patients presenting with recurrent kidney stones, especially in childhood, leading to delayed diagnosis and irreversible kidney damage.
  • Inadequate Oxalate Removal: Relying solely on conventional hemodialysis for oxalate removal in PH1 patients with ESKD, which is insufficient and leads to progressive systemic oxalosis.
  • Delaying Transplantation: Postponing referral for combined liver-kidney transplantation in PH1, particularly in patients with progressive ESKD or severe systemic oxalosis, can lead to irreversible morbidity and mortality.
  • Calcium Restriction: Advising severe dietary calcium restriction, which can paradoxically increase oxalate absorption from the gut. Instead, adequate calcium intake is recommended.

Recent Updates

• Guidelines: Several professional organizations, including the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) and American Society of Nephrology (ASN), have updated their guidelines or published consensus statements incorporating the newer RNAi therapies into the management algorithms for primary hyperoxaluria. These guidelines emphasize early genetic diagnosis and the role of targeted therapies.
• Evidence:
  • RNAi Therapies: Landmark phase 3 clinical trials (e.g., ILLUMINATE series for Lumasiran, PHYOX series for Nedosiran) have provided strong evidence for the efficacy and safety of these novel agents in reducing urinary and plasma oxalate levels in PH1 patients (and PH2 for Nedosiran). Long-term follow-up studies continue to demonstrate sustained reductions in oxalate and, in some cases, improvement or stabilization of renal function.
  • Research into new therapeutic targets and oral enzyme replacement strategies (e.g., reloxaliase for intestinal oxalate degradation) is ongoing.
• Controversies:
  • Optimal Timing of Transplantation in the RNAi Era: A key area of ongoing debate is whether RNAi therapies can sufficiently control oxalate production in PH1 to allow for isolated kidney transplantation instead of combined liver-kidney transplantation, or to significantly delay the need for transplantation. Current consensus still favors combined liver-kidney transplant as definitive for PH1, but the role of pre-transplant RNAi therapy to reduce oxalate burden is evolving.
  • Role of RNAi in PH2/PH3: While Nedosiran is approved for PH2, its long-term impact on preventing ESKD in PH2 and the potential role of similar therapies for PH3 continue to be investigated.

Key References

• Guidelines:
  • Hoppe, B. et al. "A practical guideline for the management of primary hyperoxaluria." Nephrology Dialysis Transplantation 32.Suppl 1 (2017): i1-i12. (ERA-EDTA Working Group on Inherited Kidney Diseases consensus).
  • Cochat, P., Hulton, S. A., Acquaviva C., et al. "Primary hyperoxaluria type 1: indications for therapeutic strategy." Kidney International 72.9 (2007): 1063-1069. (Older but foundational guidance).
  • Recent position statements and clinical practice points from the American Society of Nephrology (ASN) and the Oxalosis and Hyperoxaluria Foundation (OHF).
• Studies:
  • Garrelfs, S. F., et al. "Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1." New England Journal of Medicine 383.19 (2020): 1842-1851 (ILLUMINATE-A trial for Lumasiran).
  • Tanner, M., et al. "Nedosiran for Primary Hyperoxaluria Type 1 and Type 2." New England Journal of Medicine 388.22 (2023): 2029-2041 (PHYOX2 trial for Nedosiran).
• Reviews:
  • Hoppe, B. "Primary hyperoxaluria: new insights into a rare disease." Kidney International 95.2 (2019): 285-293.
  • Cochat, P., et al. "Primary hyperoxaluria: A practical approach to diagnosis and treatment." Clinical Kidney Journal 14.1 (2021): 88-99.
  • Milliner, D. S., et al. "Primary hyperoxaluria Type 1: Current and emerging therapeutic approaches." Kidney International 93.6 (2018): 1290-1300.